Index removal puts Innoviva in focus

Innoviva (INVA) has just been dropped from several Russell growth and small cap benchmarks. This type of change can prompt index-tracking funds to rebalance and may lead to increased short term trading activity in the stock.

At a share price of US$22.25, Innoviva has seen mixed momentum, with the share price return up 11.98% year to date but down over the past quarter. Longer term total shareholder returns of 16.74% over one year and 78.00% over three years indicate that investors who stayed invested have seen materially stronger outcomes.

If this index shake up has you rethinking your watchlist, it could be a good moment to look at other opportunities using the Simply Wall St screener for 40 healthcare AI stocks

For Innoviva, the recent index exit raises a simple tension: does this shuffle mostly reflect changing sentiment around the stock, or does it better align with the fundamentals investors are currently paying for?

Price-to-Earnings of 3.3x: Is it justified?

On Simply Wall St's numbers, Innoviva screens as inexpensive on earnings, with a P/E of 3.3x and a flag that the stock is trading at good value compared both to peers and to an internal fair value estimate.

The P/E ratio compares the current share price of $22.25 to the company’s earnings per share. It therefore reflects how much investors are paying for each dollar of current earnings. For a biopharmaceutical stock with a portfolio of commercial products and royalties, this metric is often used as a quick gauge of how the market is weighing present earnings against expectations for future profitability.

In Innoviva's case, several valuation checks point in the same direction. The stock is described as trading at 62.3% below an internal fair value estimate, and as "good value" relative to peers and industry. The P/E of 3.3x is also flagged as attractive versus an estimated fair P/E of 7.5x. This is a level the market could move toward if sentiment and earnings quality were seen as more aligned.

The comparison with the wider pharmaceuticals space is even more stark. Innoviva's 3.3x P/E is assessed against a peer average of 16.7x and a US pharmaceuticals industry average of 15.3x, suggesting the stock is currently being valued at a substantial discount to sector norms on an earnings basis. Explore the SWS fair ratio for Innoviva

Result: Price-to-Earnings of 3.3x (UNDERVALUED)

However, Innoviva's reliance on a concentrated royalty and product portfolio, along with annual net income that has declined 22.28%, could challenge how durable this valuation gap really is.

Another view on Innoviva’s value

Alongside the low 3.3x P/E, Innoviva also screens as inexpensive on our DCF model, which puts fair value at about $59 per share versus the current $22.25. That is a wide gap, but it also raises a simple question for you: how comfortable are you with the earnings uncertainties behind those cash flow assumptions?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Innoviva for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mixed signals around Innoviva leave you unsure, take a moment to review the underlying data, weigh the concerns against the potential upsides, and decide where you stand with the help of 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Innoviva?

If Innoviva has sharpened your focus on value and risk, do not stop here. Broaden your watchlist now using targeted screeners that surface specific types of opportunities.

• Target potential mispricings by reviewing companies highlighted in the 45 high quality undervalued stocks and see which ones fit your return and risk expectations.
• Boost income potential by scanning for higher-yield candidates using the 9 dividend fortresses and spot stocks that align with your payout goals.
• Prioritise resilience by narrowing your search to companies in the 74 resilient stocks with low risk scores and keep fragile balance sheets off your radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.